FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209179739> ?p ?o ?g. }

• W3209179739 endingPage "e591" @default.
• W3209179739 startingPage "e590" @default.
• W3209179739 abstract "Recurrent high-grade glioma (rHGG) continues to cause increased morbidity and mortality. To date, salvage therapy for rHGG remains ineffective, even with novel immune checkpoint blockade approaches. Here we evaluate molecular factors that may influence outcomes in rHGG patients treated with HFSRT and immunotherapy.This retrospective analysis identified 76 continuous rHGG patients treated with HFSRT and PD-1 inhibitors on or off trial protocol with > 3 months of follow-up from 2010 to 2020. Clinical characteristics, treatment, outcomes, and available molecular alterations in IDH1 (n = 74), PTEN (n = 54), EGFRvIII (n = 64) or amplification (n = 56), CDKN2A (n = 42), TERT (n = 42) and MGMT promoter methylation (n = 69) were collected. Time to recurrence (TTR) and overall survival (OS) were estimated from the end of HFSRT with univariable (UVA) Kaplan-Meier methods compared via log-rank test as well as Cox regression analyses.The median age at HFSRT was 55 years (range: 22-83) with a KPS of 80 (range: 50-100). The majority (63%) of patients were male, 35% had > 2 recurrences of HGG before HFSRT and 55% underwent salvage surgery. A total of 11 patients (15%) received bevacizumab (Bev) prior to HFSRT. The median HFSRT dose was 35 Gy (range: 30-40 Gy) given in 5-10 fractions. Sixty-six (87%) patients were treated with concurrent HFSRT and Bev followed by immunotherapy. At a median follow-up from HFSRT of 13.8 months (range: 8.7-18.9), 55 (72%) patients relapsed with a median TTR of 6.94 months (5.0-8.87) and OS of 10.1 months (7.4-12.9); this included Bev-naïve and -resistant patients. Bev vs no Bev with HFSRT improved TTR (13.7 vs 6.3 months, P < 0.001), though Bev with HFSRT was not associated with improved OS. Of interest, no Bev prior to HFSRT improved OS from HFSRT (12.0 vs 8.4 months, P = 0.01). No molecular factors were associated with TTR after HFSRT, though IDH1-mut (P = 0.001) and wild-type PTEN (P = 0.02) and EGFR (P = 0.02) were related with prolonged OS. Similarly, mutations in TERT were associated with inferior OS (26.7 vs 60.7 months, P < 0.001). MGMT methylation status was not associated with TTR of OS.Salvage treatments for rHGG remain a challenge. This study provides further insight into prognostic molecular determinants in the setting of HFSRT, PD-1 blockade and Bev.E. Guvenli: None. D. Grass: None. D.E. Oliver: None. A.B. Etame: None. N. Tran: None. R.J. Macaulay: None. P. Forsyth: Research Grant; NIH/NCI, CDMRP, Department of Defense, Pfizer, State of Florida - Bankhead Coley, Moffitt Center of Excellence Celgene project, NIH/NCI. Honoraria; BTG, NIH, Ziopharm, Tocagen, NCRI. Consultant; AbbVie, Inc, Ziopharm, Novellus, NCI Neuro-Oncology Branch Peer Review, Physical Sciences Oncology Network, Tocagen. Advisory Boar. S. Sahebjam: Research Grant; Merck, Bristol Myers Squibb, Brooklyn Immunotherapeutics. Advisory Board; Merck, Boehringer Ingelheim. Travel Expenses; Eli Lilly. H.M. Yu: Honoraria; UpToDate. Speaker's Bureau; BrainLab. Advisory Board; Novocure, AbbVie." @default.
• W3209179739 created "2021-11-08" @default.
• W3209179739 creator A5001880989 @default.
• W3209179739 creator A5003748444 @default.
• W3209179739 creator A5007475484 @default.
• W3209179739 creator A5007620042 @default.
• W3209179739 creator A5025331599 @default.
• W3209179739 creator A5032655726 @default.
• W3209179739 creator A5034442780 @default.
• W3209179739 creator A5072969261 @default.
• W3209179739 creator A5088103390 @default.
• W3209179739 date "2021-11-01" @default.
• W3209179739 modified "2023-09-25" @default.
• W3209179739 title "Evaluation of Molecular Determinants Related to Outcomes in Recurrent High Grade Glioma Treated With Hypofractionated Stereotactic Radiotherapy (HFSRT) and Immune Checkpoint Blockade" @default.
• W3209179739 doi "https://doi.org/10.1016/j.ijrobp.2021.07.1581" @default.
• W3209179739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701822" @default.
• W3209179739 hasPublicationYear "2021" @default.
• W3209179739 type Work @default.
• W3209179739 sameAs 3209179739 @default.
• W3209179739 citedByCount "0" @default.
• W3209179739 crossrefType "journal-article" @default.
• W3209179739 hasAuthorship W3209179739A5001880989 @default.
• W3209179739 hasAuthorship W3209179739A5003748444 @default.
• W3209179739 hasAuthorship W3209179739A5007475484 @default.
• W3209179739 hasAuthorship W3209179739A5007620042 @default.
• W3209179739 hasAuthorship W3209179739A5025331599 @default.
• W3209179739 hasAuthorship W3209179739A5032655726 @default.
• W3209179739 hasAuthorship W3209179739A5034442780 @default.
• W3209179739 hasAuthorship W3209179739A5072969261 @default.
• W3209179739 hasAuthorship W3209179739A5088103390 @default.
• W3209179739 hasBestOaLocation W32091797391 @default.
• W3209179739 hasConcept C121608353 @default.
• W3209179739 hasConcept C126322002 @default.
• W3209179739 hasConcept C143998085 @default.
• W3209179739 hasConcept C167135981 @default.
• W3209179739 hasConcept C170493617 @default.
• W3209179739 hasConcept C2776694085 @default.
• W3209179739 hasConcept C2777701055 @default.
• W3209179739 hasConcept C2777802072 @default.
• W3209179739 hasConcept C2778227246 @default.
• W3209179739 hasConcept C2778468042 @default.
• W3209179739 hasConcept C2780387249 @default.
• W3209179739 hasConcept C2780775027 @default.
• W3209179739 hasConcept C2780851360 @default.
• W3209179739 hasConcept C502942594 @default.
• W3209179739 hasConcept C50382708 @default.
• W3209179739 hasConcept C509974204 @default.
• W3209179739 hasConcept C71924100 @default.
• W3209179739 hasConcept C90924648 @default.
• W3209179739 hasConceptScore W3209179739C121608353 @default.
• W3209179739 hasConceptScore W3209179739C126322002 @default.
• W3209179739 hasConceptScore W3209179739C143998085 @default.
• W3209179739 hasConceptScore W3209179739C167135981 @default.
• W3209179739 hasConceptScore W3209179739C170493617 @default.
• W3209179739 hasConceptScore W3209179739C2776694085 @default.
• W3209179739 hasConceptScore W3209179739C2777701055 @default.
• W3209179739 hasConceptScore W3209179739C2777802072 @default.
• W3209179739 hasConceptScore W3209179739C2778227246 @default.
• W3209179739 hasConceptScore W3209179739C2778468042 @default.
• W3209179739 hasConceptScore W3209179739C2780387249 @default.
• W3209179739 hasConceptScore W3209179739C2780775027 @default.
• W3209179739 hasConceptScore W3209179739C2780851360 @default.
• W3209179739 hasConceptScore W3209179739C502942594 @default.
• W3209179739 hasConceptScore W3209179739C50382708 @default.
• W3209179739 hasConceptScore W3209179739C509974204 @default.
• W3209179739 hasConceptScore W3209179739C71924100 @default.
• W3209179739 hasConceptScore W3209179739C90924648 @default.
• W3209179739 hasIssue "3" @default.
• W3209179739 hasLocation W32091797391 @default.
• W3209179739 hasLocation W32091797392 @default.
• W3209179739 hasOpenAccess W3209179739 @default.
• W3209179739 hasPrimaryLocation W32091797391 @default.
• W3209179739 hasRelatedWork W2025724318 @default.
• W3209179739 hasRelatedWork W2126765362 @default.
• W3209179739 hasRelatedWork W2182264700 @default.
• W3209179739 hasRelatedWork W2794625586 @default.
• W3209179739 hasRelatedWork W3032476915 @default.
• W3209179739 hasRelatedWork W3107038423 @default.
• W3209179739 hasRelatedWork W3177607563 @default.
• W3209179739 hasRelatedWork W4220713473 @default.
• W3209179739 hasRelatedWork W4285038142 @default.
• W3209179739 hasRelatedWork W4296014464 @default.
• W3209179739 hasVolume "111" @default.
• W3209179739 isParatext "false" @default.
• W3209179739 isRetracted "false" @default.
• W3209179739 magId "3209179739" @default.
• W3209179739 workType "article" @default.